Treatment outcome for XXXX in a developing country: university malaya medical centre, malaysia from 2003-2010.

@entity1 @entity135 @entity5 @entity2133 @entity957 @entity213
BACKGROUND: @entity135 ( @entity135 ) is the eighth most common @entity5 as estimated from worldwide data. The incidence of @entity135 was reported as 8.5 per 100,000 population. This study was aimed to determine the treatment outcomes for @entity135 @entity1 treated in the Oncology Unit of University Malaya Medical Centre (UMMC). MATERIALS AND METHODS: All newly diagnosed @entity1 with @entity957 of @entity135 ( @entity213 ) referred for treatment to the Oncology Unit at UMMC from 2003-2010 were retrospectively analyzed. Treatment outcomes were 5-year overall survival (OS), cause specific survival (CSS), loco-regional control (LRC) and radiotherapy (RT) related side effects. Kaplan-Meier and log rank analyses were used to determine survival outcomes, stratified according to American Joint Committee on Cancer (AJCC) stage. RESULTS: A total of 130 cases were analysed. Most cases (81.5%) were at late stage (AJCC III-IVB) at presentation. The 5-year OS for the whole study population was 34.4% with a median follow up of 24 months. The 5-year OS according to AJCC stage was 100%, 48.2%, 41.4% and 22.0% for stage I, II, III and IVA-B, respectively. The 5-year overall CSS and LCR were 45.4% and 55.4%, respectively. Late effects of RT were documented in 41.4% of @entity1 . The most common late effect was @entity2133 . CONCLUSIONS: The treatment outcome of @entity213 at our centre is lagging behind those of developed nations. Efforts to increase the number of @entity1 presenting in earlier stages, increase in the use of combined modality treatment, especially concurrent chemoradiotherapy and implementation of intensity modulated radiotherapy, may lead to better outcomes for our @entity135 @entity1 .
